X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Sees Significant Increase in Short Interest

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR - Get Free Report) was the target of a large growth in short interest during the month of January. As of January 31st, there was short interest totalling 16,610,000 shares, a growth of 22.6% from the January 15th total of 13,550,000 shares. Based on an average trading volume of 5,310,000 shares, the days-to-cover ratio is presently 3.1 days.

X4 Pharmaceuticals Stock Up 1.1 %

XFOR traded up $0.01 during mid-day trading on Wednesday, reaching $0.50. 1,818,792 shares of the stock were exchanged, compared to its average volume of 5,347,314. The company has a debt-to-equity ratio of 1.26, a quick ratio of 4.80 and a current ratio of 4.89. The stock has a market capitalization of $85.94 million, a PE ratio of -5.60 and a beta of 0.12. X4 Pharmaceuticals has a 1 year low of $0.26 and a 1 year high of $1.60. The company has a 50 day moving average price of $0.60 and a two-hundred day moving average price of $0.58.

Insider Buying and Selling

In other X4 Pharmaceuticals news, CEO Paula Ragan sold 76,473 shares of the stock in a transaction on Friday, January 24th. The shares were sold at an average price of $0.45, for a total value of $34,412.85. Following the completion of the sale, the chief executive officer now owns 1,087,386 shares in the company, valued at $489,323.70. This trade represents a 6.57 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CFO Adam S. Mostafa sold 74,773 shares of X4 Pharmaceuticals stock in a transaction dated Friday, January 24th. The stock was sold at an average price of $0.45, for a total value of $33,647.85. The disclosure for this sale can be found here. Insiders have sold 202,663 shares of company stock valued at $91,198 in the last 90 days. 1.62% of the stock is owned by insiders.

Institutional Investors Weigh In On X4 Pharmaceuticals

Large investors have recently added to or reduced their stakes in the company. Verition Fund Management LLC purchased a new stake in shares of X4 Pharmaceuticals in the 3rd quarter valued at about $30,000. Cantor Fitzgerald L. P. purchased a new position in shares of X4 Pharmaceuticals in the fourth quarter worth $30,000. SG Americas Securities LLC purchased a new stake in shares of X4 Pharmaceuticals during the third quarter worth about $37,000. Atria Wealth Solutions Inc. purchased a new stake in X4 Pharmaceuticals in the fourth quarter worth $44,000. Finally, Wells Fargo & Company MN lifted its holdings in X4 Pharmaceuticals by 51.7% in the fourth quarter. Wells Fargo & Company MN now owns 78,518 shares of the company's stock worth $58,000 after buying an additional 26,763 shares during the period. Hedge funds and other institutional investors own 72.03% of the company's stock.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on the stock. HC Wainwright restated a "buy" rating and issued a $1.50 price target on shares of X4 Pharmaceuticals in a research note on Friday, February 7th. Stifel Nicolaus cut their target price on shares of X4 Pharmaceuticals from $5.00 to $4.00 and set a "buy" rating on the stock in a research report on Thursday, November 14th.

X4 Pharmaceuticals Company Profile

X4 Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia.